SC Slams Hospitals and Centre Over Steep Drug Markups
Understanding the Apex Court Scrutiny on Medicine Price Markups
The Supreme Court of India strongly reprimanded the Union government over steep medicine price markups. A bench comprising Justices Vikram Nath and Sandeep Mehta questioned why regulatory frameworks persistently favour manufacturers over struggling citizens. In addition, the apex court observed that the National Pharmaceutical Pricing Authority appears totally defunct. Consequently, the judges demanded clear justifications for exorbitant margins on essential pharmaceuticals.
The court reviewed public interest petitions demanding price ceilings across non-scheduled medications and medical consumables. Currently, the Drugs Prices Control Order regulates only scheduled essential formulations. However, non-scheduled medicines constitute more than eighty percent of the domestic market. Therefore, pharmaceutical companies exercise significant latitude when setting maximum retail prices. As a result, out-of-pocket healthcare expenses continue to push vulnerable families toward economic distress.
The Wide Chasm Between PTR and MRP
The bench highlighted glaring disparities between the price to retailer and the maximum retail price. For instance, the judges noted that retailers purchase intravenous drip lines for fifteen rupees and sell them for two hundred fifty rupees. Furthermore, the court examined severe price inflation involving life-saving oncology medications. In one striking example, a private hospital billed a chemotherapy injection at 1.3 lakh rupees despite an acquisition cost of 11,000 rupees.
Additional Solicitor General Aishwarya Bhati argued that Indian drug prices remain among the lowest globally. However, the bench swiftly rejected this international comparison. The judges insisted that authorities cannot evaluate drug affordability without considering low per capita income. Moreover, Justice Mehta warned the government against weighing vulnerable patients against commercial profit. Similarly, the court stressed that genuine calibration cannot explain ten-fold price surges.
Hospital Margins and Economic Realities in India
Senior counsel Mukul Rohatgi defended private healthcare institutions during the proceedings. He asserted that private hospitals maintain round-the-clock emergency infrastructure and face substantial operational costs. However, the Supreme Court unequivocally rejected this defense. The bench declared that commercial hospitals cannot justify survival through predatory pricing practices. Instead, institutions must find legitimate revenue avenues rather than inflating medical consumables by hundreds of percent.
Additionally, the petitions urged the court to mandate generic drug prescriptions across all clinical settings. Petitioner Kishan Chand Jain highlighted that manufacturers exploit non-scheduled categories to inflate profit margins. Consequently, medical practitioners and hospital administrators face imminent regulatory shifts concerning procurement and billing ethics. Clinicians must stay informed as judicial scrutiny reshapes the pharmaceutical landscape.
Frequently Asked Questions
Q1: Why did the Supreme Court criticize the National Pharmaceutical Pricing Authority?
The Supreme Court criticized the NPPA as totally defunct. Specifically, the court noted that the agency failed to regulate massive disparities between retailer acquisition rates and printed maximum retail prices.
Q2: How do non-scheduled drugs differ from scheduled drugs under the DPCO?
Scheduled drugs fall under strict price ceilings fixed by the government. In contrast, manufacturers set initial prices freely for non-scheduled drugs, facing only an annual ten percent increase limit.
Q3: What solutions did the petitioners propose to curb excessive medicine markups?
The petitioners requested mandatory generic prescriptions for registered medical practitioners. Furthermore, they demanded statutory price caps on medical devices and strict trade margin rationalization across all non-scheduled pharmaceuticals.
References
- SC questions Centre over medicine price markups, says hospitals cannot survivethrough 'dacoity' - ETHealthworld
- Can you justify this loot? Supreme Court slams hospitals, government for 1,000% mark-up on cancer drugs - Bar and Bench
- Supreme Court Questions Centre Over Medicine Pricing, Calls NPPA 'Totally Defunct' - Outlook India
- 'Govt allowing this to happen': Supreme Court questions overpricing of medicines, massive gap in MRP and cost to retailers - Hindustan Times
